These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32305493)

  • 21. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction.
    Zhao Z; Ksiezak-Reding H; Riggio S; Haroutunian V; Pasinetti GM
    Schizophr Res; 2006 May; 84(1):1-14. PubMed ID: 16581231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    Khan I; Tantray MA; Alam MS; Hamid H
    Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of glycogen synthase kinase-3beta in schizophrenia.
    Koros E; Dorner-Ciossek C
    Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The relationship between the Wnt signaling and the psychiatric diseases].
    Ferrero A; Cereseto M; Sifonios L
    Vertex; 2006; 17(67):165-71. PubMed ID: 16847474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
    Medina M; Avila J
    Expert Rev Neurother; 2013 May; 13(5):495-503. PubMed ID: 23621307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
    Koh SH; Noh MY; Kim SH
    Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
    Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
    Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
    Amar S; Belmaker RH; Agam G
    Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.
    Medina M; Avila J
    Expert Opin Ther Targets; 2014 Jan; 18(1):69-77. PubMed ID: 24099155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor.
    Eldar-Finkelman H; VanHook AM
    Sci Signal; 2016 Nov; 9(454):c22. PubMed ID: 27902446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
    Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
    Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
    Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen synthase kinase 3: an emerging therapeutic target.
    Eldar-Finkelman H
    Trends Mol Med; 2002 Mar; 8(3):126-32. PubMed ID: 11879773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of glycogen synthase kinase-3β enhances cognitive recovery after stroke: the role of TAK1.
    Venna VR; Benashski SE; Chauhan A; McCullough LD
    Learn Mem; 2015 Jul; 22(7):336-43. PubMed ID: 26077686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.
    Thotala DK; Hallahan DE; Yazlovitskaya EM
    Cancer Res; 2008 Jul; 68(14):5859-68. PubMed ID: 18632640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lithium, a potential protective drug in Alzheimer's disease.
    Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
    Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
    Takashima A
    J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Glycogen Synthase Kinase-3: An Emerging Target in the Treatment of Traumatic Brain Injury.
    Shim SS; Stutzmann GE
    J Neurotrauma; 2016 Dec; 33(23):2065-2076. PubMed ID: 26979735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.